Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 24, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on March 21, 2025, as part of an existing buyback programme.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased (March 21, 2025): 570,000 ordinary shares
- Volume-Weighted Average Price: 1,513.93 GBp
- Price Range: 1,504.50 GBp (Low) to 1,529.00 GBp (High)
- Total Treasury Shares Held: 182,520,290
- Ordinary Shares in Issue (excluding Treasury): 4,132,694,556
- Total Voting Rights: 4,132,694,556
Material Changes
Since the commencement of the current buyback agreement on February 24, 2025, GSK has purchased an aggregate of 13,449,987 ordinary shares. The March 21 transaction represents the latest execution under this non-discretionary agreement with Citigroup Global Markets Limited.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the Risk Factors section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total number of shares remaining to be purchased under the current buyback programme.
- Confirm the total capital allocated for the buyback programme initiated on February 24, 2025.
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors referenced in the filing.
- Monitor subsequent Form 6-K filings for further repurchase activity under the non-discretionary agreement.